Ignite Creation Date:
2024-05-05 @ 9:42 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002143
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Sponsor:
Hoffmann-La Roche
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Status:
COMPLETED
Status Verified Date:
1999-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy of acitretin in the treatment of psoriasis in HIVAIDS patients
Etretinate a retinoid has proven successful in the treatment of HIV-infected patients with psoriasis but it has an elimination half-life of 100 days Acitretin a metabolite of etretinate has a much shorter half-life of 2 to 3 days Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition but it has not been thoroughly evaluated in HIV-infected patients
Etretinate a retinoid has proven successful in the treatment of HIV-infected patients with psoriasis but it has an elimination half-life of 100 days Acitretin a metabolite of etretinate has a much shorter half-life of 2 to 3 days Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition but it has not been thoroughly evaluated in HIV-infected patients
Detailed Description:
Etretinate a retinoid has proven successful in the treatment of HIV-infected patients with psoriasis but it has an elimination half-life of 100 days Acitretin a metabolite of etretinate has a much shorter half-life of 2 to 3 days Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition but it has not been thoroughly evaluated in HIV-infected patients
Patients receive acitretin daily with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index PASI Treatment continues for a total of 20 weeks Patients are followed every 2 weeks
Patients receive acitretin daily with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index PASI Treatment continues for a total of 20 weeks Patients are followed every 2 weeks
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 65-932 | None | None | None |